美国心力衰竭学会临床试验最新进展：EMOTE、HERB-CHF、BEST基因子研究及RHYTHM-ICD

Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.

作者信息

Lalukota Krishna, Cleland John G F, Ingle Lee, Clark Andrew L, Coletta Alison P

机构信息

Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU16 5JQ, UK.

出版信息

Eur J Heart Fail. 2004 Dec;6(7):953-5. doi: 10.1016/j.ejheart.2004.10.003.

DOI:10.1016/j.ejheart.2004.10.003

PMID:15556058

Abstract

This article summarises key presentations relevant to the pathophysiology, prevention or treatment of heart failure, from the Heart Failure Society of America annual meeting held in Toronto, Canada. Data from the EnoxiMone in intravenous inOTropE-dependent subjects (EMOTE) study suggest that the oral PDE-3 inhibitor enoximone may be effective for weaning severe heart failure patients from intravenous inotropic therapy. Hawthorn Extract Randomised Blinded Trial in CHF (HERB-CHF) failed to show a benefit of hawthorn extract added to conventional heart failure therapy. A genetic sub-group analysis of the Blocker Evaluation of Survival Trial (BEST) study showed that bucindolol reduced mortality and hospitalisations in patients who were homozygous for the Arg389 variant of the beta(1) adrenoceptor. In the Resynchronisation Hemodynamic Treatment for Heart Failure Management (RHYTHM-ICD) study, patients randomised to cardiac resynchronisation therapy (CRT) showed an improvement in symptoms and functional capacity compared to the control group.

摘要

本文总结了在加拿大多伦多举行的美国心力衰竭学会年会上，与心力衰竭的病理生理学、预防或治疗相关的重要报告。依诺昔酮治疗静脉注射正性肌力药物依赖受试者（EMOTE）研究的数据表明，口服磷酸二酯酶3（PDE-3）抑制剂依诺昔酮可能有助于严重心力衰竭患者从静脉注射正性肌力药物治疗中撤机。山楂提取物治疗慢性心力衰竭随机双盲试验（HERB-CHF）未能显示在传统心力衰竭治疗基础上加用山楂提取物的益处。β受体阻滞剂生存评估试验（BEST）研究的基因亚组分析表明，比索洛尔可降低β1肾上腺素能受体Arg389变体纯合子患者的死亡率和住院率。在心力衰竭管理的再同步血流动力学治疗（RHYTHM-ICD）研究中，与对照组相比，随机接受心脏再同步治疗（CRT）的患者症状和功能能力有所改善。